PharmaTalkRadio

About this podcast:  Preliminary survey results conducted by the Tufts CSDD focus on the strategic and structural growth of new trial sites and partnerships in bringing trials directly to the local communities. The preliminary survey findings also shed light on the strategic and structural growth of these new trial sites and partnerships, offering valuable insights into the evolving global clinica...

About this podcast: This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center.  Dr Rosenberg focuses on:  The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancer The potential...

About this podcast: This presentation from the 2025 IO360º Summit focuses on the immunological effects of radiopharmaceuticals, presented by Chaitanya Divgi, Sr Strategic Expert, Therapeutic Innovation, at Novartis.  Specifically, this podcast dives deeper into:  An introduction to radioligand therapy A focus on PSMA-targeted radionuclide therapy Prelimary work on the relationship between systemic...

About this episode: In this podcast, Dr Penny Heaton, Global Head of the Johnson and Johnson Office of the Chief Medical Officer, discusses:  J&J’s approach to patient centricity across the enterprise Her thoughts on balancing balancing safety and risk/benefit ratios with more engaged patients and more complex science Moving risk benefit assessments earlier into clinical development and the ne...

In this podcast, Nicole Murphy, EVP and Head of Pharmaceutical Operations & Technology at Biogen, discusses: Cross-functional collaboration to deliver value How Biogen is using AI to enhance innovation Supply chain simplification Biogen's partnership philosophy as it relates to drug delivery Their recent $2 billion manufacturing investment in the Research Triangle Park And Biogen's acquisition...

In this podcast, Kate Woda, Conference Director of the Immuno-Oncology 360° Summit, discusses what attendees can expect at the 12th annual event, including key topic areas, session highlights, presenting companies and more. For more information about the upcoming event, full agenda and speakers, visit IO360Summit.com .  

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with CMOs and advisory solutions firms about how CMOs can work with consultants and fractional talent to stay on budget while getting the expertise needed. Specifically: Different profiles of fractional consultants What to look for in a consultant and how to ensure alignment with the team Scoping the role of f...

About this podcast: This podcast dives deep into the fundamentals of antibody-drug conjugate design, specifically focusing on the selection of targeting antibodies, cytotoxic drugs, and linkers. Presenter Dr Deepa Pakianathan highlights key strategies for constructing ADCs and the critical differentiating features that enhance therapeutic efficacy and safety.  For more information, go to IO360summ...

About this podcast: This podcast comes from the 2025 Patients as Partners in Clinical Research conference.  This panel discussion demonstrates how patient advocates are bridging the divide at the site level to improve patient representation in clinical trials. More specifically, this podcast focuses on:  Strategies for overcoming limited resources and lack of infrastructure, which can hinder inclu...

About this podcast:  Liz Thompson, Global Development Leader, Senior Clinical Development Scientist at Roche, presented how the organization had delivered a single, cohesive protocol amendment categorization process to reduce the number of amendments and create a continuous improvement strategy, all to speed up timelines and reduce costs. This presentation comes from the September 2025 DPHARM: Dis...

About this podcast: This session was recorded at the September 2025 CRAACO: Clinical Research as a Care Option conference. Rural sites represent untapped potential for reaching a broader array of patients and providing them access to life-changing clinical trials, but existing clinical trial infrastructure does not set rural sites up for success.  Funded through the Genentech Innovation Fund, Mont...

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs about how CMOs can support value creation in biotechs and how that is influenced buy the current biotech financial climate. Specifically: The importance of storytelling and leading thoughtfully Effective prioritization and execution towards the company narrative Balancing the team to be lean...

In this podcast from the DPHARM 2024 archives, Biogen discussed how they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients  with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition.  For more informatio...

At the March 2025 Patients as Partners conference, Merck presents how they advancing patient and community engagement through targeted initiatives designed to improve trial participation, relevance, and long-term impact. Key topics include: Identifying and addressing patient and community needs Strategies for earning trust and fostering sustained engagement Key collaborations and partnerships driv...

Summary:  This session was recorded at the March 2025 Patients as Partners conference. In this session, Pfizer addressed how they were working to ensure continuity in the patient insights they were collecting, throughout the product life cycle. This included:  Approaches for aligning internal processes to facilitate the seamless flow of patient insights from early-phase to late-phase teams Suggest...

Summary:  From the DPHARM Archives, this podcast was recorded at the September 2024 DPHARM conference. In this podcast, BMS present how they specifically targeted the challenge of recruiting patients for clinical trials, aiming to make the process faster and easier. By bringing trials directly to patients, their ultimate objective was to significantly expedite patient enrollment. In this case exam...

About this podcast: Recorded at the 2025 Immuno-Oncology 360º Summit, Stanford University's Dr Crystal Mackall shares work from her lab developing GD2-targeting CAR T cell therapy for the treatment of deadly pediatric brain tumor, as well as broader lessons on the evolution of cell therapy, and her forward-looking perspective on shaping the next generation of cancer treatments. For more informatio...

Summary: Rescuing a clinical trial and choosing to switch vendor's mid-trial are some of the most expensive decisions biotech CMOs can make. These rescues require a significant amount of time, money and energy and may not even address the root issue behind a trial's poor performance. In this podcast, Raul Lima, SVP, Strategic Clinical Operations, inSeption Group, discusses a scaffolding approach t...

Summary: When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kyma...

In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part III of this podcast series covers sessions addressing AI in Clinical Trials.

Summary: Accessibility to CAR-T is limited by traditional manufacturing, with its associated challenges and high cost. Moffitt Cancer Center's Chief BioEngineering Officer, Dr Greg Sawyer, highlights Moffitt's significant progress in enhancing T cell potency and boosting efficacy through engineering strategies. Dr Sawyer discusses assays enabling precise asessment of T cell potency, developments i...

Summary: In this podcast, Pharma and Drug Delivery executives from Novartis, AstraZeneca, Merck and Quotient Sciences discuss traditional and novel approaches to improve the oral delivery of peptides including: The biopharmaceutics of oral peptide and the use of permeation enhancers Alternate sites for the delivery of oral peptides throughout the GI tract Improving oral exposure through ingestible...

Summary:  In this podcast, Dr Anthony Yanni, SVP, Head of Patient Centricity at Astellas, presented the business rationale for patient-centric medicine development, how it's disrupting the pharmaceutical industry and why companies have to act swiftly to remain competitive.  Dr Yanni discusses how to align medicine development with healthcare delivery and the necessary cultural transformation that...

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs across indications about how CMOs can better develop drugs patients want and derisk development by partnering with patient organizations. Specifically, the panelists address: Patient voice driving drug development forward Supporting health equity and patient access after approval Building gen...

Summary: In this session, pharma sponsors and sites gather to present innovative solutions to solve site challenges in workforce and capability gaps, increasing technology burden, patient enrollment and managing clinical trial protocol complexity. They discuss efforts to address those challenges, early impacts and outcomes.  In this panel:  Dennis Salotti, MS, MBA, Executive Director & Head of...